Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antoine Italiano

Showing results (261-270 of 418) with videos related to

Pageof 42
Sort By:
European Journal of Cancer (Oxford, England : 1990)|October 28, 2023
Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancerClara Helal, Cédric Pobel, Arnaud Bayle, et al.
Targeted Oncology|November 10, 2020
Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid TumorsJean-Pierre Delord, Antoine Italiano, Ahmad Awada, et al.
European Journal of Cancer (Oxford, England : 1990)|February 7, 2016
Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life settingStéphane Bouchet, Sylvie Poulette, Karine Titier, et al.
European Journal of Cancer (Oxford, England : 1990)|August 6, 2022
Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours: Long-term follow-up of nilotinib in TGCTGeert Spierenburg, Peter Grimison, Christine Chevreau, et al.
The Lancet. Oncology|March 25, 2018
Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trialHans Gelderblom, Claire Cropet, Christine Chevreau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2021
Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib StudyAlbiruni R Abdul Razak, Sebastian Bauer, Cristina Suarez, et al.
International Journal of Cancer|September 25, 2021
Treatment of 120 adult osteosarcoma patients with metachronous and synchronous metastases: A retrospective series of the French Sarcoma GroupElise Lavit, Mihaela Aldea, Sophie Piperno-Neumann, et al.
Plos One|September 19, 2018
EPIGIST: An observational real-life study on patients with metastatic gastrointestinal stromal tumors receiving imatinibOlivier Bouché, Axel Le Cesne, Maria Rios, et al.
European Journal of Cancer (Oxford, England : 1990)|August 15, 2021
Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATEPatrick Schöffski, Michaela Kubickova, Agnieszka Wozniak, et al.
European Journal of Cancer (Oxford, England : 1990)|May 8, 2026
Integrating tumor volumetry and liquid biopsy: a New model to define prognosis in advanced pancreatic ductal adenocarcinomaVictor Robic, Maxime Collin, Jules Dupont, et al.
Pageof 42

Showing results (261-270 of 418) with videos related to

Sort By:
Pageof 42
European Journal of Cancer (Oxford, England : 1990)|October 28, 2023
Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancerClara Helal, Cédric Pobel, Arnaud Bayle, et al.
Targeted Oncology|November 10, 2020
Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid TumorsJean-Pierre Delord, Antoine Italiano, Ahmad Awada, et al.
European Journal of Cancer (Oxford, England : 1990)|February 7, 2016
Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life settingStéphane Bouchet, Sylvie Poulette, Karine Titier, et al.
European Journal of Cancer (Oxford, England : 1990)|August 6, 2022
Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours: Long-term follow-up of nilotinib in TGCTGeert Spierenburg, Peter Grimison, Christine Chevreau, et al.
The Lancet. Oncology|March 25, 2018
Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trialHans Gelderblom, Claire Cropet, Christine Chevreau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2021
Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib StudyAlbiruni R Abdul Razak, Sebastian Bauer, Cristina Suarez, et al.
International Journal of Cancer|September 25, 2021
Treatment of 120 adult osteosarcoma patients with metachronous and synchronous metastases: A retrospective series of the French Sarcoma GroupElise Lavit, Mihaela Aldea, Sophie Piperno-Neumann, et al.
Plos One|September 19, 2018
EPIGIST: An observational real-life study on patients with metastatic gastrointestinal stromal tumors receiving imatinibOlivier Bouché, Axel Le Cesne, Maria Rios, et al.
European Journal of Cancer (Oxford, England : 1990)|August 15, 2021
Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATEPatrick Schöffski, Michaela Kubickova, Agnieszka Wozniak, et al.
European Journal of Cancer (Oxford, England : 1990)|May 8, 2026
Integrating tumor volumetry and liquid biopsy: a New model to define prognosis in advanced pancreatic ductal adenocarcinomaVictor Robic, Maxime Collin, Jules Dupont, et al.
Pageof 42